Axsome Therapeutics (AXSM) Capital Expenditures (2015 - 2026)

Axsome Therapeutics has disclosed Capital Expenditures across 12 years of filings, most recently posting $121000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $121000.0, down 64.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $263000.0 (down 48.43% YoY), and the FY2025 annual result was $480000.0, up 77.78% from the prior year.
• Capital Expenditures came in at $121000.0 for Q1 2026 at Axsome Therapeutics, up from $71000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $371000.0 in Q3 2023 to a low of $7000.0 in Q4 2023.
• The 5-year median for Capital Expenditures is $90000.0 (2024), against an average of $126764.7.
• Across the five-year window, Capital Expenditures soared 40033.04% in 2022 and plunged 96.13% in 2023, its largest moves.
• Axsome Therapeutics' Capital Expenditures stood at $181000.0 in 2022, then slumped by 96.13% to $7000.0 in 2023, then jumped by 328.57% to $30000.0 in 2024, then jumped by 136.67% to $71000.0 in 2025, then surged by 70.42% to $121000.0 in 2026.
• The last three Capital Expenditures figures came in at $121000.0 (Q1 2026), $71000.0 (Q4 2025), and $58000.0 (Q3 2025), per Business Quant data.